Interestingly, although the assessment of BRAF mutations nowadays is essential in clinical oncology practice, per the most recent AJCC and NCCN guidelines, only lactate dehydrogenase (LDH) is currently used for staging and prognostication, but the results can only be interpreted in advanced-stage melanoma due to LDH being a general marker of inflammation [20]. The gene discussed is BRAF; the disease is melanoma.